Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 21, Issue 7, 2003, Pages 1285-1292

  Mac Manus, Michael P ^a   Hicks, Rodney J ^a   Matthews, Jane P ^a   McKenzie, Allan ^a   Rischin, Danny ^a   Salminen, Eeva K ^a   Ball, David L ^a  

^a UNIVERSITY OF TURKU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; FREE RADICAL;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; HUMAN; INTERMETHOD COMPARISON; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; SCANNING ELECTROCHEMICAL MICROSCOPY; TREATMENT RESPONSE; AGED; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; LUNG TUMOR; MALE; MIDDLE AGED; MORTALITY; PROSPECTIVE STUDY;

AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FLUORODEOXYGLUCOSE F18; FREE RADICALS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0038701664     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.07.054     Document Type: Article

References (42)

1. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
2. Green S, Weiss GR: Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 10:239-253, 1992
3. Komaki R, Cox JD, Hartz AJ, et al: Characteristics of long-term survivors after treatment for inoperable carcinoma of the lung. Am J Clin Oncol 8:362-370, 1985
4. Mac Manus MP, Wada M, Matthews JP, et al: Characteristics of 49 patients who survived for 5 years following radical radiation therapy for non-small cell lung cancer: The potential for cure. Int J Radiat Oncol Biol Phys 46:63-69, 2000
5. Dillman RO, Seagren SL, Propert KJ, et al: A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 323:940-950, 1990
6. Non-Small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 311:899-909, 1995
7. Werner-Wasik M, Xiao Y, Pequignot E, et al: Assessment of lung cancer response after nonoperative therapy: Tumor diameter, bidimensional product, and volume-A serial CT scan-based study. Int J Radiat Oncol Biol Phys 51:56-61, 2001
8. McLoud TC, Bourgouin PM, Greenberg RW, et al: Bronchogenic carcinoma: Analysis of staging in the mediastinum with CT by correlative lymph node mapping and sampling. Radiology 182:319-323, 1992
9. Lever AM, Henderson D, Ellis DA, et al: Radiation fibrosis mimicking local recurrence in small cell carcinoma of the bronchus. Br J Radiol 57:178-180, 1984
10. Vansteenkiste JF, Stroobants SG, Dupont PJ, et al: Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxyglucose-positron emission tomography scan in non-small-cell lung cancer: An analysis of 125 cases-Leuven Lung Cancer Group. J Clin Oncol 17:3201-3206, 1999
11. Coleman RE: PET in lung cancer. J Nucl Med 40:814-820, 1999
12. Schiepers C, Haustermans K, Geboes K, et al: The effect of preoperative radiation therapy on glucose utilization and cell kinetics in patients with primary rectal carcinoma. Cancer 85:803-811, 1999
13. Price P, Jones T: Can positron emission tomography (PET) be used to detect subclinical response to cancer therapy? The EC PET Oncology Concerted Action and the EORTC PET Study Group. Eur J Cancer 31A:1924-1927, 1995
14. 18F- fluorodeoxy-glucose positron emission tomography in preoperative evaluation of lung cancer. Lancet 344:1265-1266, 1994
15. Vansteenkiste JF, Stroobants SG, De Leyn PR, et al: Lymph node staging in non-small-cell lung cancer with FDG-PET scan: A prospective study on 690 lymph node stations from 68 patients. J Clin Oncol 16:2142-2149, 1998
16. Scott WJ, Schwabe JL, Gupta NC, et al: Positron emission tomography of lung tumors and mediastinal lymph nodes using [18F]fluorodeoxyglucose: The Members of the PET-Lung Tumor Study Group. Ann Thorac Surg 58:698-703, 1994
17. Weder W, Schmid RA, Bruchhaus H, et al: Detection of extrathoracic metastases by positron emission tomography in lung cancer. Ann Thorac Surg 66:886-892, 1998
18. 18F-fluorodeoxyglucose positron emission tomography. Am J Roentgenol 168:1357-1360, 1997
19. Bury T, Barreto A, Daenen F, et al: Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer. Eur J Nucl Med 25:1244-1247, 1998
20. Mac Manus MP, Hicks RJ, Matthews JP, et al: High rate of detection of unsuspected distant metastases by PET in apparent stage III non-small-cell lung cancer: Implications for radical radiotherapy. Int J Radiat Oncol Biol Phys 50:287-293, 2001
21. Mac Manus MP, Hicks RJ, Ball DL, et al: F-18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with nonsmall cell lung carcinoma: Powerful correlation with survival and high impact on treatment. Cancer 92:886-895, 2001
22. Mac Manus MP, Wong K, Hicks RJ, et al: Early mortality after radical radiotherapy for non-small-cell lung cancer: Comparison of PET-staged and conventionally-staged patients treated at a large tertiary referral center. Int J Radiat Oncol Biol Phys 52:351-361, 2002
23. 18F-FDG PET for suspected recurrent non-small cell lung cancer after potentially curative therapy: Impact on management and prognostic stratification. J Nucl Med 42:1605-1613, 2001
24. Mountain CF: Revisions to the International System for Staging Lung Cancer. Chest 111:1710-1717, 1997
25. Grossi M, Millward M, Fisher R, et al: Combined modality treatment using concurrent radiotherapy and pharmacologically-guided carboplatin for inoperable and incompletely resected non-small cell lung cancer. Lung Cancer 31:73-82, 2001
26. Karp JS, Muehllehner G, Mankoff DA, et al: Continuous-slice PENN-PET: A positron tomograph with volume imaging capability. J Nucl Med 31:617-627, 1990
27. Young H, Baum R, Cremerius U, et al: Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: Review and 1999 EORTC recommendations. Eur J Cancer 35:1773-1782, 1999
28. Schemper M, Smith TL: A note on quantifying follow-up in studies of failure time. Control Clin Trials 17:343-346, 1996
29. Muhm JR, Brown LR, Crowe JK, et al: Comparison of whole lung tomography and computed tomography for detecting pulmonary nodules. Am J Roentgenol 131:981-984, 1978
30. Langendijk HA, Lamers RJ, ten Velde GP, et al: Is the chest radiograph a reliable tool in the assessment of tumor response after radiotherapy in nonsmall cell lung carcinoma? Int J Radiat Oncol Biol Phys 41:1037-1015, 1998
31. Webb WR, Gatsonis C, Zerhouni EA, et al: CT and MR imaging in staging non-small cell bronchogenic carcinoma: Report of the Radiologic Diagnostic Oncology Group. Radiology 178:705-713, 1991
32. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
33. Hebert ME, Lowe VJ, Hoffman JM, et al: Positron emission tomography in the pretreatment evaluation and follow-up of non-small cell lung cancer patients treated with radiotherapy: Preliminary findings. Am J Clin Oncol 19:416-421, 1996
34. Vansteenskiste JF, Stroobants SG, De Leyn PR, et al: Potential use of FDG-PET scan after induction chemotherapy in surgically staged IIIa-N2 non-small-cell lung cancer: A prospective pilot study-The Leuven Lung Cancer Group. Ann Oncol 9:1193-1198, 1998
35. Erdi YE, Macapinlac H, Rosenzweig KE, et al: Use of PET to monitor the response of lung cancer to radiation treatment. Eur J Nucl Med 27:861-866, 2000
36. Patz EF Jr, Connolly J, Herndon J: Prognostic value of thoracic FDG-PET imaging after treatment for non-small cell lung cancer. Am J Roentgenol 174:769-774, 2000
37. McGuirt WF, Greven K, Williams D, et al: PET scanning in head and neck oncology: A review. Head Neck 20:208-215, 1998
38. Weber WA, Ott K, Becker K, et al: Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric unction by metabolic imaging. J Clin Oncol 19:3058-3065, 2001
39. Wahl RL: Current status of PET in breast cancer imaging, staging, and therapy. Semin Roentgenol 36:250-260, 2001
40. Bar-Shalom R, Mor M, Yefremov N, et al: The value of Ga-67 scintigraphy and F-18 fluorodeoxyglucose positron emission tomography in staging and monitoring the response of lymphoma to treatment. Semin Nucl Med 31:177-190, 2001
41. Wirth A, Seymour JF, Hicks RJ, et al: Can F-18 fluorodeoxyglucose 3ositron emission tomography (PET) replace Gallium-67 scanning (GA) for staging Hodgkin's disease and non Hodgkin's lymphoma (NHL)? Am J Med 112:262-268, 2002
42. Mac Manus MP, Hicks RJ, Matthews JP, et al: Survival and freedom from metastasis after radical radiotherapy/chemoradiotherapy for non-small cell lung cancer show powerful correlation with fdg-pet response. Proc Am Soc Clin Oncol 21:338a, 2002 (abstr 1348)